Shire, Actavis Feud Over Unresolved Issues At Lialda IP Trial
A lack of definitive rulings from the Federal Circuit on certain issues in Shire's suit over Actavis' proposed generic version of its gastrointestinal drug Lialda emerged as a major point of...To view the full article, register now.
Already a subscriber? Click here to view full article